Elan Skelaxin FTC Inquiry Ongoing Despite Halt To Patent Listing Investigation

The Federal Trade Commission is continuing its inquiry into Elan's competitive practices for Skelaxin despite halting an investigation of whether the firm wrongfully listed a patent for the muscle relaxant

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet